Heike Zurhold

Heike Zurhold

Auto-generated profile, based on publicly available information

Heike Zurhold

Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
MMMarcus-Sebastian Martens
Marcus-Sebastian Martens
HZHeike Zurhold
Heike Zurhold
MRMoritz Rosenkranz
Moritz Rosenkranz
AOAmy O’dOnnell
Amy O’dOnnell
Michelle AddisonMichelle Addison
Michelle Addison
UVUwe Verthein
Uwe Verthein
Background: Amphetamine-type stimulants (ATS) are the second most commonly used illicit drugs in Europe and globally. However, there is limited understanding of what shapes patterns of ATS use over the life course. The ATTUNE project “Understanding Pathways to Stimulant Use: a mixed methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe” aims to fill this gap. Here we report initial findings from the life course chart exercise conducted as part of qualitative interviews with ATS users and nonusers. Methods: Two hundred seventy-nine in-depth qualitative interviews were conducted with five ATS user groups (current and former dependent users;current and former frequent users;non-frequent users) and one group of exposed non-ATS users in five European countries (Germany, UK, Poland, Netherlands and Czech Republic). As part of the interviews, we used life course charts to capture key life events and substance use histories. Life events were categorised as either positive, neutral or negative, and associated data were analysed systematically to identify differences between user groups. We applied statistical analysis of variance (ANOVA) and analysis of covariance (ANCOVA) to test for group differences. Results: Out of 3547 life events documented, 1523 life events were categorised as neutral, 1005 life events as positive and 1019 life events as negative. Current and formerly dependent ATS users showed more negative life events for the entire life course after age adjustment. Although some group differences could be attributed to the individuals’ life course prior to first ATS use, most negative life events were associated with periods of ATS usage. A detailed analysis of the specific life domains reveals that dominantly, the social environment was affected by negative life events. Conclusions: For non-dependent, frequent and non-frequent ATS users, negative life events from the period of ATS use do not become obvious in our analysed data. Besides preventing a pathway into ATS dependency, the aim of an intervention should be to reduce the harm by for example drug testing which offers also the opportunity for interventions to prevent developing a substance use dependency. For the group of dependent ATS users, our study suggests holistic, tailored interventions and specialist treatment services are needed, as a single, simple intervention is unlikely to cover all the life domains affected.

20 January 2013 in Journal of Gambling Studies
Verified
Journal Article
Closed access
PDF file
HZHeike Zurhold
Heike Zurhold
UVUwe Verthein
Uwe Verthein
JKJens Kalke
Jens Kalke

27 January 2016 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
MRMoritz Rosenkranz
Moritz Rosenkranz
NKNina Kerimi
Nina Kerimi
MTMadina Takenova
Madina Takenova
AIAntti Impinen
Antti Impinen
MMMirlan Mamyrov
Mirlan Mamyrov
MMMarcus-Sebastian Martens
Marcus-Sebastian Martens
In Central Asia, there is a need to update information about the situation of people who use (opioid) drugs (PWUD), especially regarding their access to and utilization of health care services. The aim of the study was to gather information about two different groups of drug users in Kazakhstan and Kyrgyzstan. In 2013, two groups of PWUD were recruited in Kazakhstan and in Kyrgyzstan in order to gather quantitative data via interviewer-administered questionnaires. PWUD registered with the Narcological Register were allocated to group A while non-registered PWUD were allocated to group B. Interviews were conducted in the office of the Narcological Register as well as in low-threshold facilities. Participants reported about their drug use patterns, health status, and utilization of health services as well as barriers to utilization. The sample consisted of N = 600 PWUD (301 registered and 299 non-registered PWUD) from Kazakhstan and N = 900 PWUD (450 registered and 450 non-registered PWUD) from Kyrgyzstan. Both groups—registered (group A) and non-registered (group B)—consisted of mainly male long-term intravenous opioid users. We found high rates of current (last 30 days) opioid use (group A up to 70 %; group B up to 84 %). Most PWUD were burdened with poor physical and mental health. The prevalence of infectious diseases added up to 19 % (group A) or 13 % (group B) regarding HIV, 56 % (group A) or 30 % (group B) regarding HCV, and 24 % (group A) or 20 % (group B) regarding tuberculosis. Registered and non-registered PWUD reported high rates (95 or 82 %) of lifetime use of health services for PWUD. Drug-related services were utilized less often, especially among the non-registered PWUD (13 %). The most important barriers preventing PWUD from accessing services were the belief not to need treatment, doubts about the effectiveness of treatment, mistrust of treatment regime/staff, and fear of being registered with the Narcological Register (mainly group B). Results show that access to the health care system for non-registered PWUD is realized mainly through low-threshold facilities. Opioid substitution treatment, which is an important pillar in the treatment of PWUD, is normally only available for those registered with the Narcological Register. Instead, access to opioid substitution treatment (especially in Kazakhstan) should be expanded and granted without prior registration, as this poses an important barrier for PWUD’s utilization of drug treatment services. Further, there seems to be a need for the provision of specific and target group-related information about drug treatment services in order to reduce existing reservations among PWUD as to the necessity and effectiveness of modern drug treatment.

23 February 2011 in Journal of Offender Rehabilitation
Verified
Journal Article
Closed access
HZHeike Zurhold
Heike Zurhold
JMJacek Moskalewicz
Jacek Moskalewicz
CSCristina Sanclemente
Cristina Sanclemente
GSGabriele Schmied
Gabriele Schmied
DSDavid Shewan
David Shewan
UVUwe Verthein
Uwe Verthein
The main objective of this follow-up study is to explore factors influencing the success or failure of women in reintegrating after their release from prison. Female drug users in five European cities were tracked after being released from prison. Out of 234 female prisoners contacted in prisons, 59 were included in the follow-up study. Structured questionnaires were given out and statistical group comparisons were conducted. The authors found that receiving preparation for release significantly supports a successful reintegration. On the other hand, living with a current drug user and initiating regular heroin use at an early age of less than 18 years are major barriers to successful reintegration.

12 April 2022 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
NLNienke Liebregts
Nienke Liebregts
RRRafaela Rigoni
Rafaela Rigoni
PPPetruželka Petruželka
Petruželka Petruželka
MBMiroslav Barták
Miroslav Barták
TUThe Maria Grzegorzewska University
The Maria Grzegorzewska University
KSKatrin Schiffer
Katrin Schiffer
Background: Amphetamine-type stimulants (ATS) are globally widely used. Scientific literature generally defines four phases of substance use (initiation, continuation, increase and decrease); however, there is limited understanding of what influences these different phases of ATS use. The ATTUNE study investigated which factors shape individual phases of use, or ATS use patterns. In this article, we report on these phases into and out of ATS use, and propose a set of recommendations for prevention, harm reduction and treatment of the different phases of ATS use. Methods: Qualitative, semi-structured interviews (n = 237) were conducted in five different European countries with participants who had used ATS, varying from a few times in a lifetime to daily. Results: Amphetamine and MDMA were the most commonly used ATS. Yet, types of ATS used differed between the countries. We found that people who use ATS have various motives for and dynamic patterns of ATS use with alternating phases of increase, continuation, decrease and sometimes dependence. Cessation was pursued in different ways and for diverse reasons, such as mental health problems and maturing out. Availability seemed not an issue, regardless of the type of ATS, phase or country. Conclusions: These findings demonstrate that tailor-made interventions are needed for the diverse types of people who use ATS and different phases or patterns of ATS use, to reduce possible harms of use. We recommended a set of interventions for the different ATS phases. These include drug checking services, peer-led information, self-management of ATS use, mental health support to help people cope with stressful life events and prevent uncontrolled use, and follow-up support after treatment.

4 December 2015 in Drugs: Education, Prevention and Policy
Verified
Journal Article
Closed access
PDF file
HZHeike Zurhold
Heike Zurhold
HSHeino Stöver
Heino Stöver
Aims: The aim of the study was to survey the availability, coverage and quality of harm reduction and drug treatment services delivered to drug users in prisons across Europe. Methods: A survey was conducted between 2012 and 2013 among the 29 European countries. An electronic semistructured questionnaire was sent to the national institutions responsible for prison services, and 27 countries responded. In addition, good practice interventions for drug offenders have been collated by 15 national experts covering 15 European countries. The interventions were described and assessed as to their quality through using European monitoring centre for drugs and drug addiction (EMCDDA) standard tools for reporting and quality assessment. Findings: Drug treatment including detoxification and opioid substitution treatment (OST) is available in prisons of most European countries. However, OST is unavailable in five countries. Almost all countries provide prison-based harm reduction measures to prevent and treat infectious diseases among prisoners. Especially, testing and treatment for HIV and tuberculosis are provided, while other measures, such as the distribution of condoms or bleach, and especially needle and syringe programmes are still rare. Conclusions: Access to and coverage of OST in prisons is higher in countries with a long history of OST provision, while in countries that introduced OST more recently the scale of OST is usually lower. Access to hepatitis C treatment is often limited in prisons due to the lack of drug abstinence or a health insurance.